Trial record 1 of 4 for:    SYMPLICITY HTN-2
Previous Study | Return to List | Next Study

Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2) (HTN-2)

This study has been completed.
Information provided by (Responsible Party):
Medtronic Vascular Identifier:
First received: April 24, 2009
Last updated: May 4, 2015
Last verified: May 2015
An international, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation in patients with uncontrolled hypertension.

Condition Intervention
Uncontrolled Hypertension
Device: Renal Denervation (Symplicity® Renal Denervation System)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)

Resource links provided by NLM:

Further study details as provided by Medtronic Vascular:

Primary Outcome Measures:
  • Office Systolic Blood Pressure Reduction [ Time Frame: Baseline to 6 months ] [ Designated as safety issue: No ]
    The primary effectiveness endpoint is change in Office Systolic Blood Pressure (SBP) from baseline to 6 months post-randomization.

Enrollment: 106
Study Start Date: June 2009
Study Completion Date: May 2015
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Renal Denervation
Renal Denervation and maintenance of anti-hypertensive medications
Device: Renal Denervation (Symplicity® Renal Denervation System)
Catheter-based renal denervation
No Intervention: Control
Maintenance of anti-hypertensive medications with option for cross-over treatment after 6-months


Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • systolic blood pressure >=160mmHg (>=150 mmHg for type 2 diabetics);
  • on 3 or more antihypertensive medications
  • >= 18 and =< 85 years of age.

Exclusion Criteria:

  • renal artery abnormalities
  • eGFR < 45mL/min
  • MI, angina, CVA within 6 months
  • Type 1 diabetes
  • ICD or pacemaker, or any other metallic implant not compatible with MRI
  • others
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00888433

Alfred Hospital
Melbourne, Australia
Vienna General Hospital
Vienna, Austria
Cliniques Universitaires Saint Luc
Brussels, Belgium
Hopital Européen Georges Pompidou
Paris, France
Herzzentrum Bad Krozingen
Bad Krozingen, Germany
Universität zu Köln
Cologne, Germany
Universitaetsklinikum Dusseldorf
Dusseldorf, Germany
University of Erlangen at Nuremburg
Erlangen, Germany
Universitaetsklinikum Essen
Essen, Germany
CardioVascular Center Frankfurt
Frankfurt, Germany
Universitatskliniken des Saarlandes
Homburg, Germany
University of Leipzig - Herzzentrum
Leipzig, Germany
Universitatsklinikum Schleswig-Holstein, Luebeck Campus
Leubeck, Germany
Pauls Stradins Clinical University Hospital
Riga, Latvia
Samodzielna Pracownia Hemodynamiczna
Warsaw, Poland
Hospital 12 de Octubre
Madrid, Spain
Universitaatsspital Zurich
Zurich, Switzerland
United Kingdom
Kent and Canterbury Hospital
Canterbury, United Kingdom
University of Glasgow
Glasgow, United Kingdom
Barts and the London School of Dentistry & Medicine
London, United Kingdom
Sponsors and Collaborators
Medtronic Vascular
Principal Investigator: Murray Esler, MBBS The Baker IDI Heart & Diabetes Institute
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Medtronic Vascular Identifier: NCT00888433     History of Changes
Other Study ID Numbers: TP-058 
Study First Received: April 24, 2009
Results First Received: September 13, 2013
Last Updated: May 4, 2015
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by Medtronic Vascular:
renal denervation
sympathetic nervous system

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases processed this record on May 26, 2016